Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Nab-Paclitaxel Plus SOC Chemo Fails to Improve OS in Newly Diagnosed Advanced Biliary Tract Cancer

January 30th 2025

Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.

T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer

January 29th 2025

T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.

Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers

January 29th 2025

Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.

Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs

January 29th 2025

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma

January 29th 2025

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

177Lu-edotreotide Improves PFS in Grade 1/2 GEP-NETs in Phase 3 COMPETE Trial

January 28th 2025

177Lu-edotreotide prolonged PFS vs everolimus in patients with inoperable, progressive, grade 1 or 2 gastroenteropancreatic neuroendocrine tumors.

Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

January 28th 2025

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

January 27th 2025

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer

January 25th 2025

Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.

Neoadjuvant SCRT Plus Cadonilimab/Chemo Meets pCR End Point in pMMR/MSS Rectal Cancer

January 25th 2025

The phase 2 NeoCaCRT trial evaluating neoadjuvant SCRT plus cadonilimab/chemotherapy met its primary end point of pCR rate in locally advanced rectal cancer.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Addition of CRT to Chemotherapy Does Not Improve RFS in Resected Gallbladder Cancer

January 25th 2025

Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.

Certepetide Plus Gemcitabine and Nab-Paclitaxel Shows Preliminary Activity in Metastatic Pancreatic Cancer

January 25th 2025

Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.

Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC

January 24th 2025

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract

January 24th 2025

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

Pembrolizumab Plus Lenvatinib and Chemo Misses OS End Point in Gastroesophageal Adenocarcinoma

January 24th 2025

OS was not improved with pembrolizumab plus lenvatinib and chemotherapy vs chemotherapy alone in advanced HER2-negative gastroesophageal adenocarcinoma.

Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer

January 24th 2025

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer

January 24th 2025

Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer

January 23rd 2025

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer

January 23rd 2025

Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.